Bharat Parenter. Q2 FY27 Earnings Call — Analysis (NSE: BPLPHARMA)
Bharat Parenterals achieved a turnaround to profitability in Q2FY27 as consolidated revenue rose 110% YoY to ₹136.3 Cr with EBITDA margin expanding to 17.3%, powered by Innoxel's operating leverage and the commencement of US CMO commercial shipments.
Result quality: stable — Results context unavailable. Management sentiment: optimistic.
The take
Q2FY27 Consolidated Revenue ₹136.3 Cr ( +110.1% YoY ) . New guidance — FY27 bpl standalone fy27 revenue gro… 10% to 15% . New story: Innoxel commercial inflection and US supply .
Results
Consolidated revenue surged 110.1% YoY to ₹136.3 Cr with EBITDA turning positive to ₹23.6 Cr (17.3% margin) and PAT reaching ₹11.8 Cr compared to a net loss of ₹8.6 Cr in Q2FY26.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹136.3 Cr | +110.1% | yoy · Q2FY27 · vs ₹64.6 Cr in Q2FY26 |
| Consolidated Revenue | ₹136.3 Cr | +45.0% | qoq · Q2FY27 · vs Q1FY27 |
| Consolidated EBITDA | ₹23.6 Cr | +2850% | yoy · Q2FY27 · vs ₹0.8 Cr in Q2FY26 |
| Consolidated EBITDA Margin | 17.3% | +820bps | qoq · Q2FY27 · vs 9.1% in Q1FY27 |
| Consolidated PAT | ₹11.8 Cr | yoy · Q2FY27 · turned positive vs loss of ₹8.6 Cr in Q2FY26 | |
| Consolidated H1 Revenue | ₹230.0 Cr | +27.0% | yoy · H1FY27 · vs H1FY26 |
| Consolidated H1 EBITDA | ₹32.1 Cr | +120.0% | yoy · H1FY27 · margin improved to 14.0% from 8.1% |
| Standalone Revenue | ₹78.6 Cr | +88.4% | yoy · Q2FY27 · vs Q2FY26 |
| Standalone EBITDA Margin | 9.0% | -330bps | qoq · Q2FY27 · vs 12.3% in Q1FY27 due to 5% higher input raw material costs |
| Standalone Order Book | ₹117.0 Cr | point_in_time · Q2FY27 · As of Sep 30, 2026 | |
| Innoxel Revenue | ₹44.5 Cr | +253.0% | yoy · Q2FY27 · vs Q2FY26 |
| Innoxel EBITDA Margin | 33.0% | qoq · Q2FY27 · vs EBITDA loss of ₹1.8 Cr in Q1FY27 | |
| Varenyam Healthcare Revenue | ₹19.7 Cr | +33.2% | yoy · Q2FY27 · vs Q2FY26 |
| Consolidated Cash Flow from Operations | ₹83.3 Cr | +116.9% | none · H1FY27 · vs ₹38.4 Cr for full year FY26 |
| Consolidated Borrowings | ₹160.0 Cr | point_in_time · Q2FY27 · As of Sep 30, 2026, primarily situated at Innoxel |
Guidance
Management reaffirmed FY27 guidance across all three operating entities, projecting 10-15% revenue growth and 10-15% EBITDA margin for Standalone, 35-45% revenue growth with 20-25% margin for Innoxel, and 20-25% growth with 8-13% margin for Varenyam Healthcare.
What management committed to
- We are going for exhibit batches [for Innoxel's liposomal program] sometime in November [2026] and subsequently be ready for filing the product in Q1 of next financial year [Q1FY28]. — Q1FY28
- We expect the second contract manufacturing product to be commercialized within FY27 upon receiving the approval from the US FDA. — FY27
- Our first 505(b)(2), which is a CDMO product and not a CMO product, is that Q3 FY28. — Q3FY28
- For the standalone business, revenue growth of 10% to 15% on FY26 base of INR 234 crores and an EBITDA margin of 10% to 15% remains consistent. — 10% to 15%, FY27
- For Innoxel, revenue growth of 35% to 45% at a margin of 20% to 25% with out-licensing income of roughly INR 80 crores to INR 90 crores. — 35% to 45%, FY27
- For Varenyam Healthcare, growth of 20% to 25% at a margin of 8% to 13% was the guidance. — 20% to 25%, FY27
- We are targeting completion of the construction [of Varenyam Biolifesciences facility] by second quarter of calendar year 2028. — Q2FY29
- We expect no further dilution at this moment in time. Using bank debts as well as the equity, the balance of the capex would be funded at Varenyam as well as Innoxel. — no further dilution, FY28
Key themes
Commercial inflection and CDMO scale-up
How the narrative shifted
- Innoxel commercial inflection and US supply: Innoxel is shifting from developmental and milestone fees to recurring commercial manufacturing and profit-share revenue, delivering dramatic operating leverage.
- Standalone margins pressured by input costs: Geopolitical conflicts drove raw material prices up by ~500 bps in Q2, weighing on gross margins for orders locked before input price rises.
- Biologics CDMO pivot at Varenyam Bio: VBPL is strategically pivoting to fill a global capacity void in mammalian pilot-scale to commercial scale-up for biosimilars and biologic innovators.
- Domestic specialty expansion via Varenyam Healthcare: Expanding domestic hospital presence beyond anaesthesia/critical care into women's health through the new 'Bhuvah' division.
Operational commentary
- Innoxel commenced commercial US supply on October 20, 2026, exporting its first CMO product (an oral liquid for a US specialty generic partner).
- Innoxel holds an EIR from US FDA inspections and EU GMP certification from Belgian authorities covering all four manufacturing lines.
- Innoxel's liposomal skid scale-up in the general block is completed; exhibit batches are scheduled for November 2026 with US filing targeted for Q1FY28.
- Varenyam Biolifesciences (VBPL) capital work-in-progress stood at ₹33.7 Cr towards a ₹300 Cr Phase 1 CDMO mammalian biologics facility targeting construction completion by Q2CY28.
- Varenyam Healthcare expanded its approved medical representative field force to 229 (targeting 250 by year-end) and is preparing to launch a second hospital division, 'Bhuvah', in gynaecology and women's health.
- Standalone business completed ORABS upgrades, QC lab expansion, and water system improvements in preparation for an upcoming EU GMP audit in FY27.
- Completed a ₹139 Cr preferential issue from marquee institutional investors (White Oak, Aurum, Ashoka India Equity) to fund subsidiary expansions, lowering promoter holding to 59.3% with zero pledge.
Analyst Q&A
Q. What is the commercialization timeline and pipeline potential for Innoxel's 13 advanced assets across FY28-FY30?
ANDAs take 15-18 months from exhibit batch to approval, while 505(b)(2)s take 12 months stability data. Management expects ANDAs and select 505(b)(2)s to launch across FY28-FY29, with most current pipeline assets in the market by FY30.
Q. What is the update on the Liposomal scale-up and yield metrics at Innoxel?
Scale-up is completed with parameters matching lab-scale results. Exhibit batches are scheduled for November 2026, positioning the dossier for US filing in Q1FY28.
Q. Can Innoxel achieve over ₹300 Cr revenue and 50-60% EBITDA margins by FY29 once commercial supply and profit share kick in?
Management declined to commit to specific FY29 figures this early, but confirmed margins will expand above 35-40% once pure profit share flows directly to the bottom line on own-developed CDMO products.
Q. How will the remaining ₹300 Cr capex for Varenyam Biolifesciences be funded beyond the ₹139 Cr preferential issue?
No further equity dilution is expected. Capex will be funded through standalone free cash flows, the ₹139 Cr equity raise, and project bank debt taken at the subsidiary level.
Q. What is the revenue potential and line utilization of the first US CMO product exported in October?
Management declined to share specific revenue numbers, stating they are awaiting binding commercial forecasts from the US partner post-commercial launch and will share more visibility in Q3.
Q. What is the gross margin differential between standalone tender and branded export business?
Management refused to share gross margins by segment, stating only that standalone full-year EBITDA will remain within the guided 10-15% band.
Research and educational content only. Not investment advice.